Results 51 to 60 of about 15,238,642 (306)

The ubiquitin system in normal and infected germinal center B cells

FEBS Letters, EarlyView.
The ubiquitin system plays a central role in germinal center (GC) B cells, influencing differentiation to long‐lived memory B cells. Oncogenic gammaherpesviruses gain access to memory B cells by establishing latency in GC B cells. Mapping ubiquitin mechanisms in normal and infected GC B cells will define specific molecular circuits in B cells germane ...
Destiny Davis, Lesly Mejia, Emily K Moser   +2 more
wiley   +1 more source

Chimeric Antigen Receptor T Cell Therapy in Hematology

Turkish Journal of Hematology, 2015
It is well demonstrated that the immune system can control and eliminate cancer cells. Immune-mediated elimination of tumor cells has been discovered and is the basis of both cancer vaccines and cellular therapies including hematopoietic stem cell ...
Pınar Ataca, Önder Arslan
doaj   +1 more source

Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report

Journal of Medical Case Reports, 2022
Background Multiple myeloma remains incurable despite treatment advancements over the last 20 years. LCAR-B38M Cells in Treating Relapsed/Refractory Multiple Myeloma was a phase 1, first-in-human, investigator-initiated study in relapsed/refractory ...
Bai-Yan Wang, Wan-Hong Zhao, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang, Ju Bai, Yan Xu, Xu-Geng Wang, Rui-Li Zhang, Li-Li Wei, Qiu-Chuan Zhuang, Frank Fan, Wang-Gang Zhang, Ai-Li He, Jie Liu   +20 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors

Nature Communications
The efficacy of Chimeric Antigen Receptor T cells against solid tumors is limited by immunosuppressive factors in the tumor microenvironment including adenosine, which suppresses Chimeric Antigen Receptor T cells through activation of the A2A receptor ...
Kevin Sek, Amanda X. Y. Chen, Thomas Cole, Jesse D. Armitage, Junming Tong, Kah Min Yap, Isabelle Munoz, Phoebe A. Dunbar, Shiyi Wu, Marit J. van Elsas, Olivia Hidajat, Christina Scheffler, Lauren Giuffrida, Melissa A. Henderson, Deborah Meyran, Fernando Souza-Fonseca-Guimaraes, Dat Nguyen, Yu-Kuan Huang, Maria N. de Menezes, Emily B. Derrick, Cheok Weng Chan, Kirsten L. Todd, Jack D. Chan, Jasmine Li, Junyun Lai, Emma V. Petley, Sherly Mardiana, Anthony Bosco, Jason Waithman, Ian A. Parish, Christina Mølck, Gregory D. Stewart, Lev Kats, Imran G. House, Phillip K. Darcy, Paul A. Beavis   +35 more
doaj   +1 more source

Antibody-conjugated lipid nanoparticles for in vivo CAR-T cell engineering: From concept to clinical translation

Nano Biomedicine and Engineering
Chimeric antigen receptor T cell therapy represents a transformative advancement in immunotherapy, wherein engineered T cells target tumor antigens, achieving high response rates in hematological malignancies.
Zhitong Guo, Mengjie Zhang, Yuanyu Huang
doaj   +1 more source

Engineering better chimeric antigen receptor T cells [PDF]

Experimental Hematology & Oncology, 2020
AbstractCD19-targeted CAR T cells therapy has shown remarkable efficacy in treatment of B cell malignancies. However, relapse of primary disease remains a major obstacle after CAR T cells therapy, and the majority of relapses present a tumor phenotype with retention of target antigen (antigen-positive relapse), which highly correlate with poor CAR T ...
Hao Zhang, Pu Zhao, He Huang
openaire   +3 more sources

Carbohydrate receptor-mediated gene transfer to human T leukaemic cells [PDF]

, 1994
The mucin-type carbohydrate Tn cryptantigen (GalNAcα1-O-Ser/Thr, where GalNAc is N-acetyl-D-galactosamine) is expressed in many carcinomas, in haemopoietic disorders including the Tn syndrome, and on human immunodeficiency virus (HIV) coat glycoproteins,
Berger, Eric G., Berger, Eric G, Mechtler, Karl, Rusconi, Sandro, Wagner, Ernst, Birnstiel, Max L., Cotten, Matt, Clausen, Erik, Dinter, André, Thurnher, Martin, Berger, Erik G., Clausen, Henrik, Birnstiel, Max L   +12 more
core   +1 more source

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

Advances in CAR-T therapy for central nervous system tumors

Biomarker Research
The application of chimeric antigen receptor T-cell therapy in central nervous system tumors has significantly advanced; however, challenges pertaining to the blood-brain barrier, immunosuppressive microenvironment, and antigenic heterogeneity continue ...
Delian Zhou, Xiaojian Zhu, Yi Xiao
doaj   +1 more source